| Title: | Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank |
| Journal: | Nature Communications |
| Published: | 9 Oct 2024 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/39384777/ |
| DOI: | https://doi.org/10.1038/s41467-024-52890-6 |
| URL: | http://dx.doi.org/10.1038/s41467-024-52890-6 |
Publication 13255
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Understanding the genetic basis of COVID-19 vaccine seroconversion is crucial to study the role of genetics on vaccine effectiveness. In our study, we used UK Biobank data to find the genetic determinants of COVID-19 vaccine-induced seropositivity and breakthrough infections. We conducted four genome-wide association studies among vaccinated participants for COVID-19 vaccine seroconversion and breakthrough susceptibility and severity. Our findings confirmed a link between the HLA region and seroconversion after the first and second doses. Additionally, we identified 10 genomic regions associated with breakthrough infection (SLC6A20, ST6GAL1, MUC16, FUT6, MXI1, MUC4, HMGN2P18-KRTCAP2, NFKBIZ and APOC1), and one with breakthrough severity (APOE). No significant evidence of genetic colocalisation was found between those traits. Our study highlights the roles of individual genetic make-up in the varied antibody responses to COVID-19 vaccines and provides insights into the potential mechanisms behind breakthrough infections occurred even after the vaccination.</p>
18 Keywords
- Aged
- Antibodies, Viral
- Biological Specimen Banks
- COVID-19
- COVID-19 Vaccines
- Female
- Genome-Wide Association Study
- HLA Antigens
- Humans
- Male
- Middle Aged
- Polymorphism, Single Nucleotide
- SARS-CoV-2
- Seroconversion
- UK Biobank
- United Kingdom
- Vaccination
- Vaccine Efficacy
6 Authors
- Marta Alcalde-Herraiz
- Martí Català
- Albert Prats-Uribe
- Roger Paredes
- JunQing Xie
- Daniel Prieto-Alhambra
1 Application
| Application ID | Title |
|---|---|
| 98358 | Real-world data linked to genetics and biomarkers to triangulate the evidence on the risk-benefit of medical products |
Enabling scientific discoveries that improve human health